Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $31,951.62 in Stock

Posted by Joseph Casey on Dec 5th, 2025

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 36,726 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $0.87, for a total transaction of $31,951.62. Following the sale, the director directly owned 3,121,694 shares of the company’s stock, valued at $2,715,873.78. The trade was a 1.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Luke Evnin also recently made the following trade(s):

On Thursday, December 4th, Luke Evnin sold 53,416 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.97, for a total transaction of $51,813.52.
On Tuesday, December 2nd, Luke Evnin sold 38,043 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total transaction of $33,858.27.
On Monday, December 1st, Luke Evnin sold 39,096 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $36,750.24.
On Friday, November 28th, Luke Evnin sold 13,014 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total transaction of $12,883.86.
On Wednesday, November 26th, Luke Evnin sold 38,978 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total transaction of $38,198.44.
On Tuesday, November 25th, Luke Evnin sold 27,297 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.92, for a total value of $25,113.24.
On Monday, November 24th, Luke Evnin sold 56,992 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $55,852.16.
On Friday, November 21st, Luke Evnin sold 41,287 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.83, for a total value of $34,268.21.
On Thursday, November 20th, Luke Evnin sold 26,411 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total value of $23,505.79.
On Wednesday, November 19th, Luke Evnin sold 42,566 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total value of $40,012.04.

Werewolf Therapeutics Stock Performance

HOWL traded up $0.08 during trading hours on Thursday, hitting $1.00. 587,802 shares of the stock were exchanged, compared to its average volume of 504,491. The stock has a market cap of $48.36 million, a price-to-earnings ratio of -0.61 and a beta of 0.74. The stock has a 50-day simple moving average of $1.42 and a 200-day simple moving average of $1.33. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87. Werewolf Therapeutics, Inc. has a 12 month low of $0.60 and a 12 month high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last issued its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. Analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of hedge funds have recently made changes to their positions in the business. MPM Asset Management LLC boosted its position in shares of Werewolf Therapeutics by 0.6% during the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after buying an additional 25,688 shares during the period. MPM Bioimpact LLC raised its stake in Werewolf Therapeutics by 0.9% during the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after acquiring an additional 20,799 shares in the last quarter. Bank of America Corp DE boosted its position in Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after acquiring an additional 25,882 shares during the period. Vanguard Group Inc. grew its stake in shares of Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after purchasing an additional 109,796 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Werewolf Therapeutics during the second quarter valued at $409,000. Institutional investors own 64.84% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Citigroup reissued a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. JMP Securities dropped their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 21st. Bank of America cut their price target on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Werewolf Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $7.75.

View Our Latest Analysis on HOWL

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.